The "Halftime Report" traders weigh in on hedge fund industry redemptions and fee structure.
The "FMHR" panel and David Maris, specialty pharmaceutical analyst at Wells Fargo Securities, discuss the latest on the EpiPen pricing outrage.
CNBC's Meg Tirrell reports the latest on the drug price debate, Teva on a generic EpiPen and the FDA. David Maris, Wells Fargo analyst, and the "FMHR" traders weigh in.
The "FMHR" traders discuss today's 'Call of the Day' which is Netflix.
The FMHR traders take their positions on four stocks making news today, including Tiffany, Signet Jewelers and more.
The "FMHR" panel discuss how hedge funds are under pressure, passive vs. active investing and which method is best.
The "Halftime Report" traders give their final trades of the show.
Kevin O'Leary, O'Shares Investments chairman, says there's nothing to lose by waiting in cash.
Richard Turnill, BlackRock global chief investment strategist, thinks emerging markets can become more sustainable and explains why he is underweight Europe.
The "FMHR" panel discuss stocks making news today including Intuit, Express, and Starbucks.
Piper Jaffray upgrades energy to overweight. The "FMHR" panel discuss this as their call of the day.
Jon Najarian tracks big options moves in Chico's.
"Halftime Report" investor Sarat Sethi bought Air Lease for his CNBC PRO model portfolio, which is up 27 percent on the year.
CNBC's Phil LeBeau reports the latest on Elon Musk's tweet about a product announcement. The "FMHR" traders and Stephanie Link, TIAA Global Asset Management, weigh in.
Dan Suzuki, BofA Merrill Lynch, shares his market forecast, and explains the key things to focus on are quality and leverage.
The "Halftime Report" experts debate whether or not to buy Tiffany and Signet going into earnings
The "FMHR" traders; Stephanie Link, TIAA Global Asset Management; and Sarat Sethi, Douglas C. Lane & Associates, take their positions on four stocks making news today, including Target, J.M. Smucker, and more.
The "FMHR" traders and Stephanie Link, TIAA Global Asset Management, discuss Mylan's EpiPen pricing saga and whether it's a new catalyst to sell Biotech.
The "Halftime Report" traders discuss Jefferies' call initiated Refiners with buy & hold ratings
Host, "Fast Money Halftime Report"
CEO and Co-founder, Ritholtz Wealth Management
Lebenthal Asset Management Chief Investment Officer
TIAA Global Asset Management Managing Director & Active Equities Portfolio Manager
Co-Founder, Najarian Family Office and Najarian Advisors
Co-Founder Najarian Family Office and Najarian Advisors
Managing Director, Principal, Portfolio Manager/Equity Analyst
Chief Market Strategist, Virtus Investment Partners
Managing Partner, Short Hills Capital Partners, LLC